- °ßÀûÁÖ¹®

- ½ÇÇèÁ¤º¸

- Áú¹®°ú ´ä

- ÀÚÀ¯°Ô½ÃÆÇ
|
Chemokine receptor, COX, Cytokine Receptor, Histamine Receptor, Immune Cell Signalingµî Immunology Research¿¡ ÇÊ¿äÇÑ agonist, antagonistµîÀ» ¼Ò°³ÇÕ´Ï´Ù. |
|
||
| Tocris | |||
| 2513 | Acyclovir | Inhibits viral DNA polymerase; antiherpetic agent |
| 1777 | Arctigenin | Potent MKK1 inhibitor. Also inhibits I¥êB¥á phosphorylation |
| 2457 | Arcyriaflavin A | Potent cdk4/cyclin D1 and CaM Kinase II inhibitor. Antiviral agent (anti-HCMV) |
| 3666 | Tenofovir | Reverse transcriptase inhibitor |
| 3299 | AMD 3100 octahydrochloride | Highly selective CXCR4 antagonist |
| 3444 | Anti-DARC | Antibody recognizing DARC |
| 3129 | BMS CCR2 22 | High affinity, potent CCR2 antagonist |
| 2769 | BX 513 hydrochloride | Selective CCR1 antagonist |
| 3581 | C 021 dihydrochloride | Potent CCR4 antagonist |
| 2423 | DAPTA | Chemokine receptor 5 (CCR5) antagonist |
| 2595 | J 113863 | Potent CCR1 chemokine receptor antagonist |
| 2089 | RS 102895 hydrochloride | CCR2b chemokine receptor antagonist |
| 2517 | RS 504393 | Highly selective CCR2 chemokine receptor antagonist |
| 2725 | SB 225002 | Potent and selective CXCR2 antagonist |
| 2724 | SB 265610 | Potent CXCR2 antagonist |
| 3650 | SB 328437 | Potent and selective CCR3 antagonist |
| 3664 | Teijin compound 1 | Potent CCR2b antagonist |
| 2757 | UCB 35625 | Potent CCR1 and CCR3 antagonist |
| 2565 | ZK 756326 | Selective, non-peptide CCR8 agonist |
| 2585 | Compstatin | C3-binding protein, inhibits complement activation |
| 3796 | Compstatin control peptide | Control peptide for Compstatin (Cat. No. 2585) |
| 2796 | (S)-(+)-Ibuprofen | Cyclooxygenase inhibitor (COX-1 > COX-2) |
| 1706 | Acetaminophen | Cyclooxygenase inhibitor; may be selective for COX-3 |
| 3461 | Anti-COX-1 | Antibody recognizing COX-1 |
| 3462 | Anti-COX-2 | Antibody recognizing COX-2 |
| 3786 | Celecoxib | Selective cyclooxygenase-2 (COX-2) inhibitor |
| 1430 | DuP 697 | Cyclooxygenase-2 (COX-2) inhibitor |
| 3871 | Etodolac | Selective cyclooxygenase-2 (COX-2) inhibitor; NSAID |
| 2776 | FK 3311 | Cyclooxygenase-2 (COX-2) inhibitor |
| 1769 | Flurbiprofen | Cyclooxygenase inhibitor |
| 1507 | FR 122047 hydrochloride | Cyclooxygenase (COX-1) inhibitor |
| 1708 | Indomethacin | Cyclooxygenase inhibitor (COX-1 > COX-2) |
| 2655 | Naproxen sodium | Cyclooxygenase inhibitor |
| 2470 | Nimesulide | Cyclooxygenase-2 (COX-2) inhibitor |
| 0942 | NS 398 | Cyclooxygenase (COX-2) inhibitor |
| 0960 | Piroxicam | Cyclooxygenase (COX-1) inhibitor |
| 1418 | Resveratrol | Cyclooxygenase inhibitor |
| 1550 | SC 560 | Cyclooxygenase (COX-1) inhibitor |
| 2895 | SC 58125 | Selective cyclooxygenase-2 (COX-2) inhibitor |
| 1707 | Sulindac | Cyclooxygenase inhibitor (following metabolism to sulindac sulfide) |
| 2580 | Tenidap | NSAID, cyclooxygenase (COX-1) inhibitor. Also opener of KIR2.3 |
| 1793 | AF 12198 | Potent, selective human type I IL-1 receptor antagonist |
| 0414 | AG 490 | EGFR-kinase inhibitor. Also JAK2, JAK3 inhibitor |
| 2446 | AS 101 | Immunomodulator; inhibits IL-10 synthesis and potentiates IL-1¥á, IL-2 and TNF-¥á release |
| 1743 | Bay 11-7085 | Irreversible inhibitor of TNF-¥á-induced I¥êB¥á phosphorylation |
| 1744 | Bay 11-7821 | Irreversible inhibitor of TNF-¥á-induced I¥êB¥á phosphorylation |
| 2743 | Caffeic acid phenethyl ester | Specific inhibitor of NF-¥êB activation |
| 3203 | Celastrol | Antioxidant and anti-inflammatory |
| 2471 | ER 27319 maleate | Selective Syk kinase inhibitor |
| 1798 | Gabexate mesylate | Serine protease inhibitor; inhibits thrombin, trypsin, kallikrein and plasmin |
| 3270 | GIT 27 | Immunomodulator; reduces production of pro-inflammatory cytokines |
| 2637 | Gliotoxin | Immunosuppressant; inhibits NF-¥êB and cytokine production |
| 2861 | HU 211* | NMDA receptor antagonist. Also NF-¥êB inhibitor |
| 2539 | IKK 16 | Selective inhibitor of IKK |
| 2611 | IMD 0354 | Inhibitor of IKK-2 |
| 2265 | Lyn peptide inhibitor | Inhibits Lyn-dependent activities of IL-5 receptor; cell-permeable |
| 1554 | Piceatannol | Inhibits TNF-induced NF-¥êB activation |
| 1093 | Pirfenidone | Antifibrotic agent; regulates cytokine levels in vivo |
| 1794 | Ro 26-4550 trifluoroacetate | Competitive inhibitor of IL-2/ IL-2R¥á receptor interaction |
| 3318 | SC 514 | IKK-2 inhibitor; attenuates NF-¥êB-induced gene expression |
| 2008 | SKF 86002 dihydrochloride | p38 MAP kinase inhibitor; anti-inflammatory agent |
| 2798 | Stattic | Selective STAT3 inhibitor |
| 3543 | Suplatast tosylate | Th2 cytokine synthesis inhibitor; antiasthmatic |
| 0652 | Thalidomide | TNF-¥á synthesis inhibitor |
| 2559 | TPCA-1 | Potent, selective inhibitor of IKK-2 |
| 3253 | Triptolide | Inhibits TNF-¥á-induced NF-¥êB activation |
| 2816 | Withaferin A | Inhibits NF-¥êB activation |
| 1675 | YM 90709 | Interleukin-5 receptor antagonist |
| 2671 | Budesonide | Synthetic glucocorticoid; anti-inflammatory and chemopreventive |
| 3685 | Corticosterone | Endogenous glucocorticoid |
| 1126 | Dexamethasone | Anti-inflammatory glucocorticoid |
| 2007 | Fluticasone propionate | Selective high affinity glucocorticoid agonist |
| 3572 | GSK 650394 | Serum- and glucocorticoid-regulated kinase (SGK) inhibitor |
| 1479 | Mifepristone | Progesterone and glucocorticoid antagonist |
| 3570 | Z-Guggulsterone | Broad spectrum steroid receptor ligand. More active isomer of Cat. No 2013 |
| 0569 | (R)-(-)-¥á-Methylhistamine dihydrobromide | Potent, standard H3 agonist |
| 1425 | (S)-(+)-Dimethindene maleate | M2-selective antagonist |
| 0572 | (S)-(+)-¥á-Methylhistamine dihydrobromide | H3 agonist, less active enantiomer |
| 2478 | 2-Pyridylethylamine dihydrochloride | H1 receptor agonist |
| 2342 | 4-Methylhistamine dihydrochloride | Selective, high affinity H4 agonist |
| 3753 | A 943931 dihydrochloride | Potent and selective H4 antagonist |
| 3640 | A 987306 | Potent and selective H4 receptor antagonist |
| 0721 | Aminopotentidine | H2 antagonist |
| 0668 | Amthamine dihydrobromide | Highly selective standard H2 agonist |
| 0791 | Antazoline hydrochloride | Imidazoline ligand |
| 3489 | Astemizole | Orally active, potent H1 antagonist. Also hERG K+ channel blocker. |
| 1857 | Burimamide oxalate | Mixed H2/H3 antagonist |
| 2211 | Carcinine ditrifluoroacetate | Highly selective H3 antagonist |
| 2577 | Cetirizine dihydrochloride | Selective H1 antagonist |
| 0902 | Cimetidine | H2 antagonist, I1 agonist |
| 1453 | Clemastine fumarate | H1 antagonist |
| 0752 | Clobenpropit dihydrobromide | Highly potent H3 antagonist and H4 partial agonist |
| 2409 | Conessine | Potent and selective H3 receptor antagonist |
| 0506 | Dimaprit dihydrochloride | Standard H2 selective agonist |
| 3072 | Diphenhydramine hydrochloride | H1 receptor antagonist |
| 0508 | Doxepin hydrochloride | Highly potent H1 antagonist. Also binds to H4 receptor |
| 0743 | DPPE fumarate | Inhibitor of histamine binding at the intracellular binding site |
| 2429 | Fexofenadine hydrochloride | H1 receptor antagonist; non-sedating antiallergic agent |
| 3545 | Histamine dihydrochloride | Endogenous histamine receptor agonist |
| 0646 | HTMT dimaleate | H1 / H2 agonist |
| 0833 | ICI 162,846 | Potent H2 antagonist, active in vivo |
| 0729 | Imetit dihydrobromide | Standard H3 and H4 agonist (H3 > H4) |
| 0932 | Immepip dihydrobromide | Standard H3 agonist. Also H4 agonist |
| 2315 | Immethridine dihydrobromide | Potent H3 agonist, highly selective over H4 |
| 1858 | Impentamine dihydrobromide | Selective H3 antagonist |
| 0779 | Iodophenpropit dihydrobromide | Potent, selective H3 antagonist |
| 2441 | JNJ 10191584 maleate | Selective H4 receptor antagonist; orally active |
| 0784 | Ketotifen fumarate | H1 antagonist |
| 1944 | Loratidine | Peripheral H1 antagonist; antiallergic agent |
| 0660 | Mepyramine maleate | Selective H1 inverse agonist |
| 2947 | Methimepip dihydrobromide | Extremely selective H3 agonist |
| 2018 | Mirtazapine | Potent 5-HT2 antagonist. Also 5-HT3, H1 and ¥á2-antagonist. Antidepressant |
| 0573 | N¥á-Methylhistamine dihydrochloride | Non-selective H3 agonist |
| 2477 | Proxyfan oxalate | High affinity H3 ligand |
| 1967 | Ranitidine hydrochloride | Selective H2 antagonist |
| 2034 | ROS 234 dioxalate | Potent H3 antagonist |
| 0512 | SKF 91488 dihydrochloride | Histamine N-methyltransferase inhibitor |
| 0644 | Thioperamide | H3 antagonist and H4 inverse agonist |
| 0826 | Tiotidine | Potent, selective H2 antagonist |
| 0662 | trans-Triprolidine hydrochloride | Standard H1 antagonist, highly potent |
| 2493 | VUF 5681 dihydrobromide | Potent H3 receptor silent antagonist |
| 2494 | VUF 8430 dihydrobromide | Potent, high affinity H4 agonist |
| 1070 | Zolantidine dimaleate | Potent, centrally active H2 antagonist |
| 0776 | (S)-Methylisothiourea sulfate | Highly selective iNOS inhibitor |
| 1415 | 1400W dihydrochloride | Potent, highly selective iNOS inhibitor |
| 0951 | 2-Iminopiperidine hydrochloride | Selective iNOS inhibitor |
| 0787 | Aminoguanidine hydrochloride | Irreversible iNOS inhibitor |
| 0871 | AMT hydrochloride | Potent, selective iNOS inhibitor |
| 2866 | BYK 191023 dihydrochloride | Potent and selective inhibitor of iNOS |
| 0873 | EIT hydrobromide | Selective iNOS inhibitor, acts arginine binding site |
| 1139 | L-NIL hydrochloride | Selective iNOS inhibitor |
| 0897 | S-Isopropylisothiourea hydrobromide | iNOS inhibitor, acts arginine binding site |
| 2291 | 1,2,3,4,5,6-Hexabromocyclohexane | Inhibits JAK2 autophosphorylation |
| 0414 | AG 490 | EGFR-kinase inhibitor. Also JAK2, JAK3 inhibitor |
| 1571 | Cucurbitacin I | Selective inhibitor of STAT3/JAK2 signaling |
| 3395 | Lestaurtinib | JAK2, FLT3 and TrkA inhibitor |
| 3115 | WHI-P 154 | JAK3 kinase inhibitor. Also inhibits EGFR |
| 1367 | ZM 39923 hydrochloride | Potent, selective JAK3 inhibitor |
| 1366 | ZM 449829 | Potent, selective JAK3 inhibitor |
| 2651 | AEG 3482 | Inhibitor of JNK signaling |
| 1290 | Anisomycin | Protein synthesis inhibitor |
| 3314 | BI 78D3 | Selective, competitive JNK inhibitor |
| 1989 | c-JUN peptide | Peptide inhibitor of JNK/c-Jun interaction |
| 1565 | JIP-1 (153-163) | JNK-selective inhibitor peptide |
| 1496 | SP 600125 | Novel and selective JNK inhibitor |
| 3607 | SU 3327 | Selective JNK inhibitor |
| 2827 | TCS JNK 5a | Selective inhibitor of JNK2 and JNK3 |
| 1290 | Anisomycin | Protein synthesis inhibitor |
| 3465 | Anti-ERK2 | Antibody recognizing ERK2 |
| 3314 | BI 78D3 | Selective, competitive JNK inhibitor |
| 2344 | CGH 2466 dihydrochloride | A1, A2B and A3 antagonist and inhibitor of p38 MAPK and PDE4 |
| 2186 | CMPD-1 | Non-ATP-competitive p38¥á inhibitor |
| 2908 | EO 1428 | Selective inhibitor of p38¥á and p38¥â2 |
| 2657 | JX 401 | Potent, reversible p38¥á inhibitor |
| 2244 | p38 MAPK Inhibitor TocrisetTM | Selection of 3 p38 MAPK inhibitors (Cat. Nos. 1264, 1202 and 1962) |
| 2999 | RWJ 67657 | Potent, selective p38¥á and p38¥â inhibitor |
| 1264 | SB 202190 | Potent, selective inhibitor of p38 MAPK |
| 1202 | SB 203580 | Selective inhibitor of p38 MAPK |
| 1402 | SB 203580 hydrochloride | Selective inhibitor of p38 MAPK; water-soluble |
| 1962 | SB 239063 | Potent, selective p38 MAP kinase inhibitor; orally active |
| 2938 | SD 169 | Selective, orally active p38¥á inhibitor |
| 2008 | SKF 86002 dihydrochloride | p38 MAP kinase inhibitor; anti-inflammatory agent |
| 1850 | Exo1 | Inhibits Golgi-ER traffic; blocks exocytosis |
| 3631 | FK 506 | Potent calcineurin inhibitor; immunosuppressant |
| 1381 | GW 5074 | Potent, selective c-Raf1 kinase inhibitor |
| 3143 | KM 11060 | Corrects F508del-CFTR trafficking |
| 3185 | L-779,450 | Potent Raf kinase inhibitor |
| 1899 | Sarafotoxin S6a | Endothelin receptor agonist |
| 1174 | Sarafotoxin S6b | Endothelin receptor agonist, non-selective |
| 1175 | Sarafotoxin S6c | Selective ETB agonist |
| 1321 | ZM 336372 | Potent, selective c-Raf inhibitor |
| 3063 | 1-Naphthyl PP1 | Src family kinase inhibitor; also inhibits c-Abl |
| 1935 | Caffeic acid-pYEEIE | Phosphopeptide ligand for src SH2 domain |
| 1629 | Herbimycin A | Src family kinase inhibitor. Also Hsp90 inhibitor |
| 1331 | Lavendustin A | EGFR, p60c-src inhibitor |
| 2265 | Lyn peptide inhibitor | Inhibits Lyn-dependent activities of IL-5 receptor; cell-permeable |
| 2877 | MNS | Selective inhibitor of Src and Syk |
| 1930 | N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide | Phosphopeptide ligand for src SH2 domain |
| 1927 | N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu | Phosphopeptide ligand for src SH2 domain |
| 1397 | PP 1 | Potent, selective Src inhibitor |
| 1407 | PP 2 | Potent, selective Src inhibitor |
| 2794 | PP 3 | Negative control for PP 2 (Cat. No. 1407) |
| 1923 | pp60 c-src (521-533) (phosphorylated) | Inhibits tyrosine kinase activity of pp60c-src and pp60v-src |
| 1155 | RR-src | Tyrosine kinase substrate peptide |
| 3642 | Src I1 | Dual site Src kinase inhibitor |
| 3446 | Anti-14.3.3¥ò | DLHTLSEDSYKDST |
| 2471 | ER 27319 maleate | Selective Syk kinase inhibitor |
| 2877 | MNS | Selective inhibitor of Src and Syk |
| 1554 | Piceatannol | Inhibits TNF-induced NF-¥êB activation |
| 3202 | Echistatin, ¥á1 isoform | ¥áV¥â3 and glycoprotein IIb/IIIa (¥áIIb¥â3) inhibitor |
| 1263 | GR 144053 trihydrochloride | Glycoprotein IIb/IIIa (¥áIIb¥â3) receptor antagonist. Antithrombotic |
| 3498 | RGDS peptide | Integrin binding sequence; inhibits integrin receptor function |
| 1796 | 5-Oxo-ETE | Oxoeicosanoid receptor agonist |
| 2756 | Arachidonic acid (in TocrisolveTM 100) | Endogenous free fatty acid (in water-soluble emulsion) |
| 3138 | BAY-u 9773 | Dual CysLT1 and CysLT2 antagonist |
| 2025 | Cinalukast | Potent, selective CysLT1 (LTD4) antagonist; orally active |
| 2276 | FPL 55712 | Leukotriene receptor antagonist |
| 2307 | Leukotriene B4 | BLT1/BLT2 receptor agonist and potent chemotactic factor |
| 2208 | LY 255283 | Selective, competitive BLT2 receptor antagonist |
| 2338 | MK 571 | Potent CysLT1 (LTD4) inverse agonist. Also MRP inhibitor |
| 3026 | ONO 1078 | Selective CysLT1 antagonist |
| 1804 | SR 2640 hydrochloride | Potent, selective LTD4 /LTE4 receptor antagonist |
| 0645 | 2-TEDC | 5-, 12-, 15-Lipoxygenase inhibitor |
| 1761 | Baicalein | 5- and 12-Lipoxygenase inhibitor |
| 1304 | BW-B 70C | 5-Lipoxygenase inhibitor |
| 1311 | MK 886 | Inhibitor of 5-lipoxygenase-activating protein (FLAP) |
| 2850 | PD 146176 | Selective 15-lipoxygenase inhibitor |
| 2204 | STEARDA | Endogenous inhibitor of 5-lipoxygenase |
| 3308 | Zileuton | Orally active 5-LOX inhibitor |
| 3022 | Edelfosine | Selective PI-PLC inhibitor, also PAF receptor agonist |
| 1657 | Ginkgolide B | PAF receptor antagonist |
| 2940 | PAF (C16) | Endogenous platelet-activating factor (PAF) |
| 0571 | PCA 4248 | PAF receptor antagonist |
| 2339 | WEB 2086 | Potent PAF receptor antagonist |
| 2295 | (¡¾)-Cloprostenol sodium salt | Water-soluble PGF2¥á analog and potent FP receptor agonist |
| 3025 | AA 2414 | Thromboxane A2 (TP) receptor antagonist |
| 0671 | AH 6809 | EP1 and EP2 receptor antagonist |
| 1620 | Alprostadil | Prostaglandin. Vasodilator and antiplatelet agent in vivo |
| 2756 | Arachidonic acid (in TocrisolveTM 100) | Endogenous free fatty acid (in water-soluble emulsion) |
| 2732 | BAY-u 3405 | Dual TP/DP2 (CRTH2) receptor antagonist |
| 1442 | BMY 45778 | Non-prostanoid prostacyclin IP receptor partial agonist |
| 2989 | Epoprostenol | Endogenous IP receptor agonist |
| 0836 | ICI 185,282 | Potent thromboxane receptor antagonist |
| 2038 | Iloprost | Prostacyclin (PGI2) analog |
| 2514 | L-161,982 | Selective EP4 receptor antagonist |
| 3342 | L-798,106 | Potent and highly selective EP3 antagonist |
| 2297 | Misoprostol | Cytoprotective PGE1 analog |
| 2296 | Prostaglandin E2 | Major endogenous prostanoid |
| 1206 | SC 19220 | Selective EP1 receptor antagonist |
| 3758 | SC 51089 | Selective EP1 receptor antagonist |
| 2939 | A 83-01 | Selective inhibitor of TGF-¥âRI, ALK4 and ALK7 |
| 2902 | D 4476 | Selective CK1 inhibitor. Also inhibits TGF-¥âRI |
| 2718 | LY 364947 | Selective inhibitor of TGF-¥âRI |
| 1614 | SB 431542 | Potent, selective inhibitor of TGF-¥âRI, ALK4 and ALK7 |
| 3211 | SB 525334 | Selective inhibitor of TGF-¥âRI |
| 3269 | SD 208 | Potent ATP-competitive TGF-¥âRI inhibitor |
| 3270 | GIT 27 | Immunomodulator; reduces production of pro-inflammatory cytokines |
| 3700 | Imiquimod | Toll-like receptor 7 (TLR7) agonist |
| 2719 | RWJ 21757 | Toll-like receptor 7 (TLR7) agonist |